Anti-PVRIG antibodies and methods of use
The present invention is directed to anti-PVRIG antibodies and methods of using same.
1. A composition comprising an anti-PVRIG antibody, wherein said antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
ii) the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453.
2. A composition according to claim 1 wherein said antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453.
3. A composition according to claim 1 wherein said antibody comprises a CH1-hinge-CH2-CH3 region from human IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.
4. A composition according to claim 3 wherein said antibody comprises the CH1-hinge-CH2-CH3 region from human IgG4.
5. A composition according to claim 3 wherein said hinge region comprises mutations.
6. A composition according to claim 3 wherein said antibody comprises a CL region of human kappa 2 light chain.
7. A composition according to claim 3 wherein said antibody comprises a CL region of human lambda 2 light chain.
8. A composition comprising an anti-PVRIG antibody, wherein said antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
ii) the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1462.
9. A composition according to claim 8 wherein said antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462.
10. A composition according to claim 8 wherein said antibody comprises a CH1-hinge-CH2-CH3 region from human IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.
11. A composition according to claim 10 wherein said antibody comprises the CH1-hinge-CH2-CH3 region from human IgG4.
12. A composition according to claim 10 wherein said hinge region comprises mutations.
13. A composition according to claim 10 wherein said antibody comprises a CL region of human kappa 2 light chain.
14. A composition according to claim 10 wherein said antibody comprises a CL region of human lambda 2 light chain.
15. A composition comprising an anti-PVRIG antibody, wherein said antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDR1 comprising SEQ ID NO:885;
ii) a vhCDR2 comprising SEQ ID NO:886;
iii) a vhCDR3 comprising SEQ ID NO:887; and
b) a light chain variable domain comprising:
i) a vlCDR1 comprising SEQ ID NO:889;
ii) a vlCDR2 comprising SEQ ID NO:890;
iii) a vlCDR3 comprising SEQ ID NO:891.
16. A composition according to claim 15 wherein said antibody comprises a CH1-hinge-CH2-CH3 region from human IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.
17. A composition according to claim 16 wherein said antibody comprises the CH1-hinge-CH2-CH3 region from human IgG4.
18. A composition according to claim 16 wherein said hinge region comprises mutations.
19. A composition according to claim 16 wherein said antibody comprises a CL region of human kappa 2 light chain.
20. A composition according to claim 16 wherein said antibody comprises a CL region of human lambda 2 light chain.